This Article Full Text Full Text (PDF) All Versions of this Article: 38/4/1229    most recent 01.STR.0000260090.90508.3ev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lip, G. Y.H. Articles by Hart, R. G. Search for Related Content PubMed PubMed Citation Articles by Lip, G. Y.H. Articles by Hart, R. G. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Atrial Fibrillation Stroke Related Collections Other Vascular biology

(Stroke. 2007;38:1229.)
© 2007 American Heart Association, Inc.

Original Contributions

High-Sensitivity C-Reactive Protein and Soluble CD40 Ligand as Indices of Inflammation and Platelet Activation in 880 Patients With Nonvalvular Atrial Fibrillation

Relationship to Stroke Risk Factors, Stroke Risk Stratification Schema, and Prognosis

Gregory Y.H. Lip, MD; Jeetesh V. Patel, PhD; Elizabeth Hughes, MD Robert G. Hart, MD

From Haemostasis Thrombosis and Vascular Biology Unit (G.Y.H.L., J.V.P., E.H.), University Department of Medicine, City Hospital, Birmingham, England, UK; University of Texas Health Science Center (R.G.H.), San Antonio, Tex.

Correspondence to Professor G.Y.H. Lip, University Department of Medicine, City Hospital, Birmingham, England, UK. E-mail g.y.h.lip{at}bham.ac.uk

Background and Purpose— There is now considerable evidence that atrial fibrillation is associated with an inflammatory state. We tested the hypothesis that plasma levels of C-reactive protein (CRP; an index of inflammation) and soluble CD40 ligand (an index of platelet activation, with links to inflammation) could be related to 3 established stroke risk stratification schema (SPAF, CHADS₂, and NICE), recognized stroke risk factors or other cardiovascular disease, and prognosis.

Methods— We studied 880 subjects with atrial fibrillation recruited from subjects receiving aspirin 325 mg/d (alone or combined with fixed inefficacious doses of warfarin) from the Stroke Prevention in Atrial Fibrillation (SPAF) III clinical trial. CRP and soluble CD40 ligand were measured by enzyme-linked immunosorbent assay.

Results— With respect to the SPAF III stroke risk stratification criteria, those with moderate to high risk had the highest levels of CRP (Kruskal Wallis test, P<0.001), but those with the highest risk had the lowest levels of soluble CD40 ligand (P=0.01). Similarly, CRP levels increased in a positive fashion with increasing stroke risk with respect to the CHADS₂ and NICE risk stratification criteria, whereas soluble CD40 ligand levels were negatively associated with stroke risk. CRP levels were higher among those patients with raised body mass index, diabetes, hypertension, ischemic heart disease, peripheral vascular disease, and recent heart failure, but not those with thromboembolism. Patients were followed-up for a mean time of 453 (standard deviation, 229) days, and all-cause mortality (log rank test, P=0.001), and vascular events (P=0.05), but not stroke, were more common in patients with high CRP levels. Soluble CD40 ligand levels were not related to stroke, vascular events, or all-cause mortality.

Conclusion— Among atrial fibrillation patients, CRP was positively correlated to stroke risk and related to stroke risk factors and prognosis (mortality, vascular events). Soluble CD40 ligand levels were lowest in those at moderate to high risk of stroke and not related to prognosis. The use of CRP in risk stratification for atrial fibrillation merits further study.

Key Words: atrial fibrillation • C-reactive protein • soluble CD40 ligand • stroke

This article has been cited by other articles:

				R. G. Hart and L. A. Pearce Current Status of Stroke Risk Stratification in Patients With Atrial Fibrillation Stroke, July 1, 2009; 40(7): 2607 - 2610. [Full Text] [PDF]

				J. Sanchez-Quinones, F. Marin, V. Roldan, and G.Y.H. Lip The impact of statin use on atrial fibrillation QJM, November 1, 2008; 101(11): 845 - 861. [Abstract] [Full Text] [PDF]

				C. J Boos and G. Y H Lip Inflammation and atrial fibrillation: cause or effect? Heart, February 1, 2008; 94(2): 133 - 134. [Full Text] [PDF]

				H. Duygu, V. Barisik, H. Kurt, U. Turk, E. Ercan, and S. Kose Prognostic value of plasma soluble CD40 ligand in patients with chronic non-valvular atrial fibrillation Europace, February 1, 2008; 10(2): 210 - 214. [Abstract] [Full Text] [PDF]

				A. Choudhury, B. Freestone, J. Patel, and G. Y. H. Lip Relationship of Soluble CD40 Ligand to Vascular Endothelial Growth Factor, Angiopoietins, and Tissue Factor in Atrial Fibrillation: A Link Among Platelet Activation, Angiogenesis, and Thrombosis? Chest, December 1, 2007; 132(6): 1913 - 1919. [Abstract] [Full Text] [PDF]